Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

NCT03136146 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03136146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03136146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
August 9, 2017
Completion date
August 1, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute lymphoblastic leukemia, recurrent adult lymphoblastic lymphoma, recurrent burkitt leukemia, recurrent burkitt lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory acute lymphoblastic leukemia, refractory burkitt leukemia, refractory burkitt lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory lymphoblastic lymphoma